Overcoming Neuromuscular Sequelae After Severe SARS-CoV-2 Infection: A Case Report
DOI :
https://doi.org/10.25759/spmfr.470Mots-clés :
COVID-19/complications, Muscle Weakness/ rehabilitation, Neurologic Manifestations/rehabilitation, Post- Acute COVID-19 Syndrome, SARS-CoV-2Résumé
Neurologic symptoms can occur in up to 65% of COVID-19 cases. This article aims to raise awareness to such neurologic impairments. We describe the case of a 52-year-old patient who required intubation and mechanical ventilation due to severe SARS-CoV-2 infection with acute respiratory distress syndrome. After extubation, he presented tetraparesis, with plegic right upper limb, global weakness of the left upper limb, and lower limb proximal weakness without distal muscle activation. Deep tendon reflexes were either decreased or absent. Right upper limb tactile and algic hypoesthesia and distal hyperesthesia in both lower limbs were also noticed. Following extensive investigation, intensive care unit-acquired weakness and right brachial plexus injury were diagnosed. He was engaged in a rehabilitation program and showed slow yet progressive improvement. At one-year follow-up evaluation, he was capable of performing independent gait with bilateral foot-up orthosis and used a tripod for unstable floorings, but maintained a non-functional right upper limb. This article describes multiple neurologic sequelae seen in a patient with severe SARS-CoV-2 infection after Intensive Care Unit hospitalization. Neurologic involvement associated to SARS-CoV-2 infection and its respective therapeutic management must be taken into account early on by medical teams and rehabilitation care should be offered.Références
Li X, Zai J, Zhao Q, Nie Q, Li Y, Foley BT, et al. Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. J Med Virol. 2020;92:602-11. doi: 10.1002/jmv.25731.
Kase Y, Okano H. Neurological pathogenesis of SARS-CoV-2 (COVID-19): from virological features to clinical symptoms. Inflamm Regen. 2021;41:15. doi: 10.1186/s41232-021-00165-8.
Solomon T. Neurological infection with SARS-CoV-2 – the story so far. Nat Rev Neurol. 2021;17:65-6. doi: 10.1038/s41582-020-00453-w.
Carlos CR, Gerardo MM, Jaime OG, Isauro GHL, Dios APJ, Neurosurgical Group. Prevalence of neurological manifestations in COVID-19 and their association with mortality. Neurology Perspectives. 2021;1:11-6. doi: 10.1016/j.neurop.2021.03.002.
Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, Sánchez-Larsen A, Layos-Romero A, García-García J, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology. 2020;95:e1060-70. doi: 10.1212/WNL.0000000000009937.
Sharifian-dorche M, Huot P, Osherov M, Wen D, Saveriano A, Giacomini PS, et al. Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic. J Neurol Sci. 2020;417:117085. doi: 10.1016/j.jns.2020.117085.
Malik GR, Wolfe AR, Soriano R, Rydberg L, Wolfe LF, Deshmukh S, et al. Injury-prone: peripheral nerve injuries associated with prone positioning for COVID-19-related acute respiratory distress syndrome. Br J Anaesth. 2020;125: e478-80. doi: 10.1016/j.bja.2020.08.045.
Makhoul E, Aklinski JL, Miller J, Leonard C, Backer S, Kahar P, et al. A review of COVID-19 in relation to metabolic syndrome: obesity, hypertension, diabetes, and dyslipidemia. Cureus. 2022;14: e27438. doi:10.7759/ cureus.27438.
Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020;11:995-8. doi: 10.1021/acschemneuro.0c00122.
Desforges M, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L, Dubé M, et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses. 2020;12:14. doi: 10.3390/v12010014.
Hokkoku K, Erra C, Cuccagna C, Coraci D, Gatto DM, Glorioso D, et al. Intensive care unit-acquired weakness and positioning-related peripheral nerve injuries in COVID-19: a case series of three patients and the latest literature review. Brain Sci. 2021;11:1177. doi: 10.3390/brainsci11091177.
Nasuelli NA, Pettinaroli R, Godi L, Savoini C, De Marchi F, Mazzini L, et al. Critical illness neuro-myopathy (CINM) and focal amyotrophy in intensive care unit (ICU) patients with SARS-CoV-2: a case series. Neurol Sci. 2021;42:1119-21. doi: 10.1007/s10072-020-04820-9.
Cabañes-martínez L, Villadóniga M, González-rodríguez L, Araque L, Díaz-Cid A, Ruz-Caracuel I, et al. Neuromuscular involvement in COVID-19 critically ill patients. Clin Neurophysiol. 2020;131:2809-16. doi: 10.1016/j.clinph.2020.09.017.
Bagnato S, Boccagni C, Marino G, Prestandrea C, D’Agostino T, Rubino F. Critical illness myopathy after COVID-19. Int J Infect Dis. 2020;99:276-8. doi: 10.1016/j.ijid.2020.07.072.
Hermans G, Van den Berghe G. Clinical review: intensive care unit acquired weakness. Crit Care. 2015;19:274. doi: 10.1186/s13054-015-0993-7.
Sidiras G, Patsaki I, Karatzanos E, Dakoutrou M, Kouvarakos A, Mitsiou G, et al. Long term follow-up of quality of life and functional ability in patients with ICU acquired weakness – A post hoc analysis. J Crit Care. 2019;53:223-30. doi: 10.1016/j.jcrc.2019.06.022.
Van Aerde N, Van den Berghe G, Wilmer A, Gosselink R, Hermans G, COVID-19 Consortium. Intensive care unit acquired muscle weakness in COVID-19 patients. Intensive Care Med. 2020;46:2083-5. doi: 10.1007/s00134-020-06244-7.
Téléchargements
Publiée
Comment citer
Numéro
Rubrique
Licence
Os manuscritos devem ser acompanhados de declaração de originalidade, Autoria e de cedência dos direitos de propriedade do artigo, assinada por todos os Autores.
Quando o artigo é aceite para publicação é obrigatória a submissão de um documento digitalizado, assinado por todos os Autores, com a partilha dos direitos de Autor entre Autores e a Revista SPMFR, conforme minuta:
Declaração Copyright
Ao Editor-chefe da Revista da Sociedade Portuguesa de Medicina Física e Reabilitação
O(s) Autor(es) certifica(m) que o manuscrito intitulado:
____________________________________________________________________ (ref.Revista da SPMFR_________) é original, que todas as afirmações apresentadas como factos são baseados na investigação do(s) Autor(es), que o manuscrito, quer em parte quer no todo, não infringe nenhum copyright e não viola nenhum direito da privacidade, que não foi publicado em parte ou no todo e que não foi submetido para publicação, no todo ou em parte, noutra revista, e que os Autores têm o direito ao copyright.
Todos os Autores declaram ainda que participaram no trabalho, se responsabilizam por ele e que não existe, da parte de qualquer dos Autores conflito de interesses nas afirmações proferidas no trabalho.
Os Autores, ao submeterem o trabalho para publicação, partilham com a Revista da SPMFR todos os direitos a interesses do copyright do artigo.
Todos os Autores devem assinar
Data:
Nome(maiúsculas)
Assinatura
Relativamente à utilização por terceiros a Revista da SPMFR rege-se pelos termos da licença Creative Commons “Atribuição – uso Não-Comercial – Proibição de Realização de Obras derivadas (by-nc-nd)”.
Após publicação na Revista SPMFR, os Autores ficam autorizados a disponibilizar os seus artigos em repositórios das suas instituições de origem, desde que mencionem sempre onde foram publicados.
OS AUTORES DEVERÃO SUBMETER UMA DECLARAÇÃO DE CONTRIBUIÇÃO / CONTRIBUTORSHIP STATEMENT INDICANDO O TIPO DE PARTICIPAÇÃO DE CADA AUTOR NO ARTIGO. Mais informações: https://authors.bmj.com/policies/bmj-policy-on-authorship/
